Influence of severity of illness on the effects of eritoran tetrasodium (E5564) and on other therapies for severe sepsis

Shock

Volumn 36, Issue 4, 2011, Pages 327-331

  Kalil, Andre C ^a   Larosa, Steven P ^b   Gogate, Jagadish ^c   Lynn, Melvyn ^c   Opal, Steven M ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b BROWN UNIVERSITY   (United States)

^c EISAI INC   (United States)

Author keywords

APACHE II; Eritoran tetrasodium; heterogeneity; immunomodulating agents; severe sepsis; severity of illness

Indexed keywords

ANTITHROMBIN; DROTRECOGIN; ERITORAN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; PLACEBO; PROTEIN P55; TUMOR NECROSIS FACTOR RECEPTOR;

APACHE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; HUMAN; INTENTION TO TREAT ANALYSIS; INTERNATIONAL NORMALIZED RATIO; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MORTALITY; MULTIPLE ORGAN FAILURE; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; RACE; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SURVIVAL; VARIANCE;

DISACCHARIDES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERLEUKIN-6; MALE; SEPSIS; SUGAR PHOSPHATES; TREATMENT OUTCOME;

EID: 80052968260     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0b013e318227980e     Document Type: Article

References (29)

1. Cinel I, Opal SM: Molecular biology of inflammation and sepsis: a primer. Crit Care Med 37:291-304, 2009.
2. Kalil AC, Sun J: Why are clinicians not embracing the results from pivotal clinical trials in severe sepsis? A bayesian analysis. PLoS ONE 3:e2291, 2008.
3. Eichacker PQ, Parent C, Kalil A, Esposito C, Cui X, Banks SM, Gerstenberger EP, Fitz Y, Danner RL, Natanson C: Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 166:1197-1205, 2002. (Pubitemid 35222596)
4. Tidswell M, Tillis W, Larosa SP, Lynn M, Wittek AE, Kao R, Wheeler J, Gogate J, Opal SM, and the Eritoran Sepsis Study Group: Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis. Crit Care Med 38:72-83, 2010.
5. Fisher CJ Jr, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 271:1836-1843, 1994. (Pubitemid 24169697)
6. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, et al.: Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286:1869-1878, 2001. (Pubitemid 33010239)
7. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, Francois B, Guy JS, Bruckmann M, Rea-Neto A, et al.: Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 353:1332-1341, 2005. (Pubitemid 41362701)
8. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699-709, 2001. (Pubitemid 32204987)
9. Zarychanski R, Doucette S, Fergusson D, Roberts D, Houston DS, Sharma S, Gulati H, Kumar A: Early intravenous unfractionated heparin and mortality in septic shock. Crit Care Med 36:2973-2979, 2008.
10. Abraham E, Laterre PF, Garbino J, Pingleton S, Butler T, Dugernier T, Margolis B, Kudsk K, Zimmerli W, Anderson P, et al.: Lenercept ( p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit Care Med 29:503-510, 2001. (Pubitemid 32225290)
11. Abraham E, Reinhart K, Svoboda P, Seibert A, Olthoff D, Dal Nogare A, Postier R, Hempelmann G, Butler T, Martin E, et al.: Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 29:2081-2089, 2001. (Pubitemid 33063534)
12. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, et al.: Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290:238-247, 2003. (Pubitemid 37430063)
13. The Cochrane Handbook 2011. Available at http://www.cochrane-handbook. org/. Accessed March 2011.
14. Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539-1558, 2002. (Pubitemid 34746062)
15. Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 327:557-560, 2003. (Pubitemid 37088507)
16. Glasziou PP, Sanders SL: Investigating causes of heterogeneity in systematic reviews. Stat Med 21:1503-1511, 2002. (Pubitemid 34746059)
17. Assmann SF, Pocock SJ, Enos LE, Kasten LE: Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 355:1064-1069, 2000. (Pubitemid 30162810)
18. Brookes ST, Whitley E, Peters TJ, Mulheran PA, Egger M, Davey Smith G: Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. Health Technol Assess 5:1-56, 2001.
19. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gotzsche PC, Lang T, CONSORT Group (Consolidated Standards of Reporting Trials): The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 134:663-694, 2001. (Pubitemid 32322245)
20. Schmid CH, Stark PC, Berlin JA, Landais P, Lau J: Meta-regression detected associations between heterogeneous treatment effects and study-level, but not patient-level, factors. J Clin Epidemiol 57:683-697, 2004. (Pubitemid 39195218)
21. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748, 1959.
22. Thompson SG, Higgins JP: How should meta-regression analyses be undertaken and interpreted? Stat Med 21:1559-1573, 2002. (Pubitemid 34746063)
23. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J: Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 335:765-774, 1990. (Pubitemid 20106689)
24. Sharp SJ, Thompson SG, Altman DG: The relation between treatment benefit and underlying risk in meta-analysis. BMJ 313:735-738, 1996. (Pubitemid 26313078)
25. Thompson SG, Smith TC, Sharp SJ: Investigating underlying risk as a source of heterogeneity in meta-analysis. Stat Med 16:2741-2758, 1997. (Pubitemid 27496919)
26. Danner RL, Elin RJ, Hosseini JM, Wesley RA, Reilly JM, Parillo JE: Endotoxemia in human septic shock. Chest 99:169-175, 1991.
27. Marshall JC, Foster D, Vincent JL, Cook DJ, Cohen J, Dellinger RP, Opal S, Abraham E, Brett SJ, Smith T, et al.: Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis 190:527-534, 2004. (Pubitemid 38982092)
28. Klein DJ, Derzko A, Foster D, Seely AJ, Brunet F, Romaschin AD, Marshall JC: Daily variation in endotoxin levels is associated with increased organ failure in critically ill patients. Shock 28:524-529, 2007. (Pubitemid 350287436)
29. Macias WL, Nelson DR, Williams M, Garg R, Janes J, Sashegyi A: Lack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsis. Crit Care 9:R607-622, 2005.